GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million
GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics.
The deal sees GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.
This recent deal with GSK is part of a broader array of collaborations Immatics has been carrying out. In recent years, its landed deals with Amgen, Celegene and Genmab.
Immatics CEO Harpreet Singh believes it shows the potential to treat solid tumors amenable to treatment using immunotherapies. He said: “The target space that we can tap into with our platforms and technologies is approximately three to four times bigger than the CAR-T space. What we can do with TCRs is tap into intracellular targets, which are not accessible to CAR-Ts and antibodies.”
Immatics and GSK will initially work on autologous T-cell therapies, but the scope of the deal may expand into allogenic candidates and additional targets.
GSK was an early entrant into the TCR space among the big pharmaceutical corporations. Since partnering with Adaptimmune in 2014, it has continued to invest in the area while moving into R&D collaborations and manufacturing partnerships with other companies.
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …